Pulmonx Corp
$ 2.28
11.76%
10 Aug - close price
- Market Cap 87,614,000 USD
- Current Price $ 2.28
- High / Low $ 2.37 / 2.03
- Stock P/E N/A
- Book Value 0.92
- EPS -1.15
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.22 %
- ROE -0.89 %
- 52 Week High 2.89
- 52 Week Low 1.13
About
Pulmonx Corporation, a medical technology company, designs, develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. The company is headquartered in Redwood City, California.
Analyst Target Price
$3.40
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-29 | 2026-04-29 | 2026-03-04 | 2025-11-12 | 2025-07-30 | 2025-04-30 | 2025-02-19 | 2024-10-30 | 2024-07-31 | 2024-05-01 | 2024-02-21 | 2023-10-30 |
| Reported EPS | -0.24 | -0.33 | -0.25 | -0.34 | -0.38 | -0.36 | -0.33 | -0.36 | -0.35 | -0.36 | -0.36 | -0.39 |
| Estimated EPS | -0.28 | -0.33 | -0.3948 | -0.42 | -0.4 | -0.4 | -0.45 | -0.45 | -0.43 | -0.46 | -0.41 | -0.43 |
| Surprise | 0.04 | 0 | 0.1448 | 0.08 | 0.02 | 0.04 | 0.12 | 0.09 | 0.08 | 0.1 | 0.05 | 0.04 |
| Surprise Percentage | 14.2857% | 0% | 36.6768% | 19.0476% | 5% | 10% | 26.6667% | 20% | 18.6047% | 21.7391% | 12.1951% | 9.3023% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LUNG
2026-08-08 05:40:18
Pulmonx (LUNG) reported its Q2 2026 earnings, highlighting a 34% reduction in net loss and a 39% decrease in adjusted EBITDA loss, driven by cost alignment initiatives. The company reiterated its full-year revenue guidance of $90 million to $92 million and expects to return to year-over-year sales growth later in 2026, partly due to the renewal of its Chinese registration certificate and stabilizing U.S. sales force. Pulmonx also emphasized the potential of its AeriSeal product to expand the total addressable market by approximately 20% globally, with CONVERT II trial enrollment on track for completion in 2027.
2026-08-04 21:11:06
Pulmonx Corp reported its 2026 quarterly results, showing revenue of $22.76 million and a diluted EPS of ($0.24), an improvement from the prior year. The company experienced a decline in revenue due to lower procedure volumes, particularly in the U.S. and China, but saw an improved gross margin and continued commercial expansion efforts.
2026-08-03 11:00:00
Pulmonx (LUNG) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates. The Zacks rating system highlights the strong correlation between changes in future earnings potential and near-term stock price movements, suggesting positive investor sentiment and potential for stock appreciation. This upgrade places Pulmonx in the top 20% of Zacks-covered stocks based on estimate revisions, indicating a strong candidate for market-beating returns.
2026-08-01 14:48:40
Pulmonx Corporation's Q2 results showed revenues in line with predictions and smaller-than-expected statutory losses. Despite the positive earnings surprise, analysts have lowered their average price target to US$3.40, indicating reduced optimism about the company's future valuation. While revenue growth is expected to slow, it is still projected to align with the industry average.
2026-07-30 18:10:48
Lake Street has reiterated its Buy rating for Pulmonx (LUNG.US) and maintained its price target at $4. This indicates a continued positive outlook from the firm regarding the company's stock performance.
2026-07-30 01:41:21
Pulmonx (NASDAQ: LUNG) has reiterated its full-year 2026 sales guidance, keeping the range at $90.000 million to $92.000 million. This guidance is consistent with previous statements and aligns closely with the consensus analyst estimate of $90.832 million. The affirmation signals management's confidence in the company's operational performance and ability to meet financial targets for the fiscal year.
